青光眼作为首位不可逆性致盲眼病给患者、家庭和社会带来重大损害和沉重的经济负担。在视觉2020计划收官之年，中国青光眼防治工作已获得较好成绩，但仍面临严峻挑战。在未来，中国青光眼防治工作将以《2020中国青光眼指南》为蓝本，有望依托人工智能技术，实现对青光眼患者的高效、便捷、准确的筛查和诊断；以患者个体特征、疾病特点和社会环境为立足点，采取个性化和精准化治疗；结合慢病管理的全生命周期概念，实现对患者的终身监测和指导。提高我国青光眼诊治水平，减少青光眼致残致盲。
Glaucoma is a leading cause of irreversible blindness in the world. It brings great damage and heavy economic burden to patients, their families and society. Under the Vision 2020 initiative, great progress has been achieved in the glaucoma prevention and treatment in China, but there are still severe challenges ahead. In the future, the Guideline for Glaucoma Care in China (2020) will act as the blueprint of the prevention and treatment of glaucoma in China. Efficient, convenient and accurate screening and diagnosis of glaucoma will be achieved relying on the artificial intelligence technology. Personalized and precision therapy will be carried out based on individual and disease characteristics and social environment. Also, lifelong monitoring and guidance of patients will be realized in the context of the whole life cycle of chronic diseases. Glaucoma care will be further improved to continuously reduce vision impairment and blindness caused by glaucoma.
青光眼作为世界第一位不可逆致盲性眼病，如何早期发现、及时诊断、恰当治疗并坚持随访管理，一直是广大眼科临床工作者所努力的方向。当前，世界处于百年未有之大变局，中国处于近代以来最好的发展时期，两者同步交织、相互激荡。在今后的5~10年中，我国青光眼防治领域将产生很多令人瞩目的成就。笔者仅以个人对本专业粗浅的理解，对未来我国青光眼防治发展作一展望，祝愿我国防盲治盲事业取得更大进步。
Glaucoma is the first irreversible blinding eye disease in the world. How to detect early, diagnose timely, treat appropriately and adhere to follow-up management has always been the direction of Chinese ophthalmic clinical workers. At present, the world is undergoing profound changes, and China is in the best period of development since modern times. In the next 5–10 years, there will be many remarkable achievements in the field of glaucoma prevention and treatment in China. Based on our personal understanding of this specialty, we look forward to the development of glaucoma management in China in the future, and wish to make greater progress in blindness prevention and treatment in China.
